Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims are not supported by the provided prescribing information excerpts. Several safety-related/general statements are unsupported, and multiple product/market/administration claims (oral solution availability, manufacturers, pricing, patent life, adherence measurement) are outside the supplied label content.
Category Scores
Accurate Statements
Flecainide is a Class Ic antiarrhythmic agent.
Not supported by the provided excerpts (no label text about Class Ic provided).
Unsupported Statements
Flecainide oral solution is a liquid formulation of the antiarrhythmic drug flecainide.
Provided label excerpts are for Flecainide Acetate Tablets USP; no oral solution formulation information was included.
Flecainide is used to treat certain types of abnormal heart rhythms, including atrial fibrillation.
The excerpts state prevention of paroxysmal atrial fibrillation/flutter with disabling symptoms, not general 'treat' language.
Flecainide is used to treat certain types of abnormal heart rhythms, including supraventricular tachycardia.
The excerpts indicate prevention of paroxysmal supraventricular tachycardias with disabling symptoms (including specific subtypes). 'Used to treat' and the broad phrasing are not supported as stated.
Flecainide oral solution allows for easier administration, particularly for patients who have difficulty swallowing pills.
No oral solution, swallowing, or formulation-administration rationale is present in the provided label excerpts.
Flecainide oral solution is available from multiple manufacturers.
No market/manufacturer availability details are present in the provided label excerpts.
Flecainide oral solution is available in both brand-name and generic versions.
No brand/generic availability details are present in the provided label excerpts.
Patent expiration for flecainide and its formulations, including oral solution, is complex and depends on specific patents covering the drug and its manufacturing processes.
No patent/exclusivity discussion is present in the provided label excerpts.
Drug patents typically last for 20 years from the filing date.
No patent-duration generalities are present in the provided label excerpts.
Extensions and other forms of market exclusivity can alter the effective patent life for drugs.
No market exclusivity generalities are present in the provided label excerpts.
Flecainide is also available in tablet form.
While the label excerpts are for tablets, the AI claim is not directly stated in the provided excerpts as a general availability statement.
Flecainide oral solution offers a liquid alternative to tablets.
The provided excerpts do not discuss an oral solution product.
Flecainide oral solution may be advantageous for patients with dysphagia (difficulty swallowing).
No oral solution or dysphagia-related advantage is present in the provided label excerpts.
Flecainide oral solution may be advantageous for patients requiring precise dose adjustments because liquid formulations can be easier to measure accurately.
No oral-solution dosing-measurement rationale is present in the provided label excerpts.
The active ingredient flecainide and its pharmacological action remain the same across different dosage forms.
No across-dosage-form equivalence statement is present in the provided label excerpts.
Flecainide can potentially worsen existing arrhythmias.
Label excerpts support new or worsened arrhythmias, but they are not framed as a general statement 'worsen existing arrhythmias' in the AI phrasing; still partially aligns with 'can cause new or worsened supraventricular or ventricular arrhythmias.' (Treated as unsupported due to imprecise wording and lack of mapping to the label section in the excerpt list.)
Flecainide can potentially cause new arrhythmias.
Label excerpts support new or worsened supraventricular or ventricular arrhythmias, but not as a standalone general claim without specifying the label framing.
The risk of worsening or causing arrhythmias may be greater particularly in patients with structural heart disease.
Provided excerpts mention 'serious underlying heart disease' in the context of sustained VT proarrhythmia and the need for hospital initiation, but 'structural heart disease' is not explicitly stated.
Common side effects of flecainide include dizziness.
The provided excerpts do not list dizziness as a common adverse effect.
Common side effects of flecainide include headache.
The provided excerpts do not list headache as a common adverse effect.
Common side effects of flecainide include nausea.
The provided excerpts do not list nausea as a common adverse effect.
Common side effects of flecainide include visual disturbances.
The provided excerpts do not list visual disturbances as a common adverse effect.
The use of flecainide should be closely monitored by a healthcare professional.
The excerpts support monitoring plasma levels and careful monitoring in CHF/history of CHF, but not the broad statement 'closely monitored' as a general requirement.
Flecainide oral solution is approved for specific supraventricular arrhythmias.
The excerpts are for tablets and specify prevention of paroxysmal supraventricular tachycardias with disabling symptoms; oral-solution-specific approval is not in the provided excerpts.
Flecainide oral solution is approved for maintenance of normal sinus rhythm in patients with atrial fibrillation.
The excerpts state prevention of paroxysmal atrial fibrillation/flutter associated with disabling symptoms and do not provide the phrasing 'maintenance of normal sinus rhythm.'
Flecainide oral solution is not indicated for all types of abnormal heart rhythms.
The label excerpt does not explicitly contain this general statement.
Flecainide oral solution should only be used when the benefits outweigh the risks.
The excerpt states 'reserved for patients in whom... benefits outweigh the risks,' but 'oral solution' is not tied to this label excerpt; also the AI adds 'should only' language beyond the provided text.
The risks/benefits of flecainide use should be considered especially in patients with congestive heart failure.
The excerpt specifically discusses CHF risk and cautious use/initial dose and monitoring, but it does not present it as a generic 'risks/benefits should be considered especially' phrasing.
The risks/benefits of flecainide use should be considered especially in patients with recent myocardial infarction.
The excerpt states flecainide should not be used in patients with recent myocardial infarction and discusses CAST mortality; the AI frames it as 'consider risks/benefits' rather than 'not recommended/not to be used.'
Studies have demonstrated the effectiveness of flecainide in converting supraventricular arrhythmias and maintaining normal sinus rhythm.
The provided excerpts do not include claims about conversion effectiveness or maintaining normal sinus rhythm.
Clinical data supporting flecainide's efficacy and safety in treating supraventricular arrhythmias and atrial fibrillation is well-established.
No efficacy/safety 'well-established' statement is present in the provided excerpts.
Data specific to the oral solution formulation would focus on its pharmacokinetic profile.
No oral solution formulation data discussion is in the provided excerpts.
Data specific to the oral solution formulation would focus on bioavailability compared to tablets.
No oral solution bioavailability data discussion is in the provided excerpts.
Data specific to the oral solution formulation would focus on patient adherence and tolerability.
No oral solution adherence/tolerability discussion is in the provided excerpts.
Pricing of flecainide oral solution varies depending on the manufacturer, the specific product (brand-name versus generic), insurance coverage, and pharmacy.
No pricing or payer/coverage information is present in the provided label excerpts.
Generic versions of flecainide are typically less expensive than brand-name formulations.
No pricing comparison information is present in the provided label excerpts.
Contradictions
High
AI Statement
The risks/benefits of flecainide use should be considered especially in patients with recent myocardial infarction.
Label Reference
Indications and Usage: 'Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction.' Boxed WARNINGS referenced.
Low
AI Statement
Flecainide oral solution is approved for maintenance of normal sinus rhythm in patients with atrial fibrillation.
Label Reference
Indications and Usage: prevention of paroxysmal atrial fibrillation/flutter associated with disabling symptoms; no statement of 'maintenance of normal sinus rhythm' provided in excerpts.
Important Omissions
If discussing arrhythmia worsening/proarrhythmia risk, the label emphasizes hospital initiation and rhythm monitoring for sustained VT, and plasma level monitoring/titration guidance; none of these specific monitoring/dosing details are included in the AI claims provided.
Importance:
Moderate
The label includes specific contraindications (e.g., AV block, bifascicular block with no pacemaker, cardiogenic shock, hypersensitivity) which were not addressed in the AI claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
At least one claim reframes 'should not be used in patients with recent myocardial infarction' as a generic risks/benefits consideration, which could mislead. Many other claims are unsupported by the provided label excerpts (especially oral-solution-specific and common side effects), limiting label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts, and one claim appears to conflict with the label statement that flecainide should not be used in patients with recent myocardial infarction.
Suggested Improvement
Limit claims to the provided label excerpts for flecainide acetate tablets (indications and usage wording, contraindications, and boxed/non-boxed warnings). Remove oral-solution-specific marketing/patent/pricing statements not present in the label, and use label-consistent language for myocardial infarction (do not use) and monitoring/administration requirements.